Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic spontaneous urticaria

Humanistic burden and health-related quality of life

9 evidence topics · 9 sources

Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded

“This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mean DLQI scores in this study suggest that CSU has a moderate impact on patients’ HRQoL,35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Novartis Pharma AG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded

“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) DLQI score was 13.8 (11.2), with 54.2% of respondents having a score >10. More than one-third (36.5%) of respondents had a DLQI score between 21 and 30, indicating an extremely large effect on the patient's life (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech
Patient-reported burden by disease control in a multinational online survey, Novartis-funded